Hope on the Horizon: A Landmark Step in the Quest for a Peeling Skin Syndrome Cure

ASHBURN, Va. – June 02, 2026 – In the vast landscape of medical innovation, some of the most profound leaps forward happen in the quiet corners of rare disease research. Today marks one such moment. Quoin Pharmaceuticals announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for QRX003, a potential therapy for Peeling Skin Syndrome (PSS). While a regulatory filing may seem procedural, its significance cannot be overstated: it is the first-ever IND submission for this debilitating genetic disorder, which currently has no approved treatment or cure.

For the small, often overlooked community of individuals living with PSS, this filing represents more than just a corporate milestone; it is a tangible beacon of hope. Pending a 30-day FDA review, Quoin expects to launch a Phase 2 clinical trial in the latter half of 2026, moving one step closer to potentially transforming the lives of patients who have long endured their condition without therapeutic options.

The Unspoken Burden of Peeling Skin Syndrome

To understand the gravity of Quoin's announcement, one must first understand the reality of living with Peeling Skin Syndrome. PSS is not a simple cosmetic issue; it is a group of rare, inherited genodermatoses where the outermost layer of the skin continuously and excessively sheds. Caused by autosomal recessive genetic mutations—most notably in the CDSN gene for the inflammatory type—the condition disrupts the very proteins that hold the skin barrier together.

Patients suffer from a relentless cycle of symptoms. The inflammatory form of PSS can cause widespread redness, severe and chronic pruritus (itching) that disrupts sleep and daily life, and painful, peeling skin across the entire body. The constant peeling leaves the skin vulnerable, and the visible nature of the condition can lead to significant emotional distress and social isolation. Currently, management is a frustrating and often inadequate exercise in applying over-the-counter emollients and attempting to avoid triggers like heat and friction. For these patients, a world without an approved therapy is the only one they have ever known.

This IND submission is built on a foundation of promising early results. The application is supported by clinical observations from an ongoing investigator-led pediatric study where a young patient treated with QRX003 has shown significant clinical improvements over 15 months. According to the company, the treatment has been well-tolerated, with no adverse events reported, and has led to marked improvements in the patient's skin, sleep patterns, and overall quality of life.

Targeting the Biological Cascade

QRX003 is not merely a symptomatic treatment; it is designed to intervene in the underlying biological process driving the disease. The topical lotion is a broad-spectrum serine protease inhibitor. In healthy skin, a delicate balance exists between proteins that build the skin barrier and enzymes (proteases) that break them down for natural shedding. In PSS, a genetic defect leads to overactive proteases that prematurely destroy corneodesmosin, a key protein that acts as a 'cellular glue' in the epidermis. This leads to the characteristic skin barrier dysfunction and peeling.

QRX003 works by blocking these overactive serine proteases. By inhibiting the enzymatic cascade that causes the skin to break down, the therapy aims to restore the integrity of the skin barrier, reduce the constant shedding, and alleviate the painful and itchy symptoms. This mechanism-based approach is what sets it apart, offering the potential to address the root cause rather than just masking the symptoms.

This is the second major indication for QRX003, which is also being developed for Netherton Syndrome, another severe rare skin disease with a similar underlying mechanism of protease imbalance. This dual-pronged development underscores the potential of QRX003 as a versatile platform technology.

The Orphan Drug Playbook: Strategy and Significance

Quoin's move is a classic and compelling example of the modern orphan drug strategy: targeting diseases with high unmet medical needs where a company can be a pioneer. By tackling PSS, Quoin is entering a field with no competition, positioning itself to become the sole provider of a transformative therapy.

“This IND submission represents yet another significant milestone for Quoin. With QRX003 now advancing toward formal clinical development in a second rare disease indication, we believe it further underscores its versatility as a platform for the potential treatment for a number of such diseases,” said Dr. Michael Myers, CEO of Quoin Pharmaceuticals. “Quoin was the first company to submit an IND for Netherton Syndrome and we are excited to follow that up with another first IND submission, further illustrating our leadership position in this space.”

This strategy is not just altruistic; it is also commercially astute. A drug for a rare disease like PSS would almost certainly qualify for Orphan Drug Designation from the FDA, granting incentives like market exclusivity for seven years post-approval, tax credits, and waived regulatory fees. These incentives are designed to de-risk and encourage development for small patient populations that might otherwise be ignored.

Furthermore, by leveraging a single platform (QRX003) across multiple rare dermatologic indications, Quoin creates significant R&D and commercial efficiencies. The company is also developing a second platform, QRX009, for other rare conditions, signaling a deep commitment to becoming a dominant force in the rare dermatology space. As Dr. Myers noted, “With these assets, we are rapidly building what we believe is becoming one of the most robust and commercially valuable pipelines in the rare dermatology space.”

The Road Ahead: From IND to Clinic

With the IND application now in the hands of the FDA, a 30-day countdown begins. If the agency raises no objections or clinical holds within this period, Quoin will have the green light to proceed with its planned Phase 2 study. The trial is expected to be a small, focused effort, recruiting 6-8 pediatric and adult patients in the United States and Europe, reflecting the rarity of the disease.

For the PSS community, this next phase of development will be watched with bated breath. The journey from an IND filing to an approved, commercially available drug is long and fraught with uncertainty. However, for the first time, there is a clear path forward. Quoin's work at this intersection of genetic science, pharmaceutical innovation, and unmet patient need exemplifies the powerful promise of modern medicine to bring life-changing solutions to those who have been waiting the longest.